Follows blood fat levels for 2 years after spleen surgery in cirrhosis
Follows blood fat levels after spleen removal surgery in adults with liver cirrhosis.
Plain-language title generated from the registry record
Registry title: Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
Key facts
- Where
- Yangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with liver cirrhosis, an enlarged spleen and a past bleed from portal hypertension, who are having keyhole spleen removal surgery (LSD). It follows their blood fats for 2 years.
- Age
- 18 to 80 years
- Sex
- Men and women can join.
- Disease stage
- Confirmed liver cirrhosis with an enlarged spleen and hypersplenism, and a past bleed from varices in the food pipe or stomach caused by portal hypertension. Liver function must be Child-Pugh Class A or B.
- Earlier treatment
- No lipid-lowering drugs, hormones or other drugs that affect blood fats within 1 month before surgery.
Main reasons for not taking part
- Child-Pugh Class C liver cirrhosis
- Previous abdominal surgery that rules out safe keyhole surgery
- Severe heart, lung or brain blood vessel problems, cancer, or primary blood disorders
- Familial hyperlipidemia, uncontrolled severe diabetes, thyroid problems or nephrotic syndrome
- Pregnancy or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07588334, who can take part
Where in China
- Clinical Medical College of Yangzhou UniversityYangzhou, ChinaContact: Guo-Qing Jiang, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Northern Jiangsu People's Hospital
- Trial code
- NCT07588334
- Record updated
- 14 May 2026
- Original description
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.Read full original descriptionShow less
A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Lipid Profiles in Patients With Liver Cirrhosis, Portal Hypertension Bleeding.
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.
Inclusion: Age 18-80 years, male or female; Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging); Splenomegaly and hypersplenism; History of portal hypertension bleeding (esophageal and gastric variceal bleeding ); Child-Pugh Class A or B liver function; Signed written informed consent; Ability to complete 24-month follow-up.
Exclusion: Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection; Metabolic/endocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery; Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery; Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders; Infections/inflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases; Child-Pugh Class C liver cirrhosis; Pregnancy or lactation; Poor compliance, inability to complete follow-up.